GermanyGermany

EMA approves BF-200 ALA

15.12.2011

Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its drug for the treatment of actinic keratosis. There was no recommendation for a restriction or temporal limitation of the approval. The substance, which Biofrontera had dubbed BF-200 ALA while in development, will now be marketed under the name Ameluz. The positive assessment report by the Committee for Medicinal Products for Human Use (CHMP) will now be forwarded to the European Commission for the formal conclusion of the process. Biofrontera anticipates final approval in December. After that, Ameluz can be commercialised in all 27 countries of the EU as well as Norway, Iceland and Liechtenstein, the company stated. Biofrontera began the application process in September of 2010.

GermanyGermany

12.10.2010

Berlin - The World Health Summit is underway for its second visit to Berlin. The international conference is organised by the M8 Alliance of leading Academic Health Centers and Medical Universities and will go on until October...

GermanyGermany

11.10.2010

Hanover - From October 5-7 the Biotechnica in Hanover attracted 9.500 visitors and 500 enterprises. This is the smallest edition for years. "In view of framework conditions currently affecting the biotech industry, this is a...

GermanyGermany

23.09.2010

Tuebingen – Private German immunotherapy specialist immatics biotechnologies GmbH has raised EUR53.8 million in a Series C financing round With new funds that the company will use to push its lead cancer vaccine IMA901 into a...

GermanyGermany

15.09.2010

Hanover – Addex Pharmaceuticals SA, Apeiron AG and and Galapagos Genomics NV have been chosen as finalists for this year’s European BIOTECHNICA Award. From Switzerland, Austria and Belgium respectively, one of the three firms...

GermanyGermany

01.09.2010

Most rare diseases are hereditary but their exact cause often remains unclear. Researchers at the Max Planck used Next generation sequencing to unravel the causative gene behind the rare hereditary mental retardation disorder...

GermanyGermany

19.08.2010

Cologne/Carlsbad – Protein expression provider CEVEC Pharmaceuticals has signed a co-exclusive worldwide licensing agreement with Life Technologies Corporation. Under the terms of the agreement, Life Technologies and CEVEC will...

GermanyGermany

17.08.2010

Monheim – German supplier of specialty chemicals and nutritional ingredients Cognis has launched the first milk for reducing blood cholesterol on the Chinese market. The novel food, which is enriched with natural phytosterols,...

Displaying results 81 to 90 out of 454

< Previous 81-90 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/8/article/ema-approves-bf-200-ala.html

Print Magazine

Product of the week

Products

Events

All Events

Current issue

All issues